BioCryst Pharmaceuticals, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2009 | $-16.2M | $-16.8M | $604.0K | $5.5M |
| FY2010 | $-28.6M | $-28.9M | $325.0K | $6.3M |
| FY2011 | $-32.3M | $-32.3M | $55.0K | $4.8M |
| FY2012 | $-37.4M | $-37.5M | $113.0K | $4.2M |
| FY2013 | $-26.5M | $-26.6M | $30.0K | $4.4M |
| FY2014 | $-38.6M | $-38.7M | $106.0K | $10.2M |
| FY2015 | $-13.1M | $-18.2M | $5.1M | $9.7M |
| FY2016 | $-53.4M | $-58.7M | $5.3M | $8.5M |
| FY2017 | $-41.1M | $-41.5M | $328.0K | $12.6M |
| FY2018 | $-92.6M | $-92.9M | $366.0K | $9.4M |
| FY2019 | $-89.6M | $-89.9M | $343.0K | $17.7M |
| FY2020 | $-135.1M | $-135.6M | $514.0K | $14.8M |
| FY2021 | $-142.2M | $-144.5M | $2.4M | $34.6M |
| FY2022 | $-161.9M | $-163.2M | $1.4M | $44.7M |
| FY2023 | $-95.1M | $-97.3M | $2.2M | $55.6M |
| FY2024 | $-52.0M | $-53.1M | $1.1M | $65.4M |
| FY2025 | $347.4M | $344.9M | $2.5M | $85.1M |